BPC-157 for Tendon Injuries: The Evidence
Peptides for Sports Injury Rehab
35 preclinical studies
A 2025 systematic review found 35 preclinical studies of BPC-157 for musculoskeletal injuries and only 1 clinical study. The evidence base is almost entirely animal data.
Vasireddi et al., HSS Journal, 2025
Vasireddi et al., HSS Journal, 2025
View as imageTendon injuries account for 30-50% of all sports-related injuries, and tendons heal slowly because of their limited blood supply. Among the peptides investigated for sports injury rehabilitation, BPC-157 (body protection compound-157) has accumulated the largest preclinical evidence base for tendon repair, with studies dating back to 2003 showing accelerated healing in rat Achilles tendon models. A 2025 systematic review published in the HSS Journal found 35 preclinical studies and only 1 clinical study across all musculoskeletal applications.[1]
BPC-157 is a synthetic 15-amino-acid peptide derived from a protein in human gastric juice. It is not approved by any drug regulatory agency for tendon repair or any other indication. WADA banned it under the S0 Unapproved Substances category in 2022, and professional athletes who test positive face sanctions. Despite this, its use among recreational and competitive athletes has grown, driven by word-of-mouth and social media rather than clinical trial evidence. For a broader overview of the compound, see BPC-157: The Body Protection Compound.
Key Takeaways
- BPC-157 accelerated transected Achilles tendon healing in rats, increasing load to failure and Young's modulus while improving histological organization (Staresinic et al., 2003)
- The peptide promotes tendon cell outgrowth from explants, protects cells against oxidative stress, and stimulates migration via the FAK-paxillin pathway (Chang et al., 2011)
- BPC-157 upregulates growth hormone receptor expression in tendon fibroblasts, potentially enhancing responsiveness to endogenous growth hormone (Chang et al., 2014)
- A 2025 systematic review found 35 preclinical studies of BPC-157 for musculoskeletal injuries but only 1 clinical study (Vasireddi et al., 2025)
- The first human IV safety pilot (2 participants, 3-day escalating doses) reported no adverse events but provides minimal safety data (Lee et al., 2025)
- No randomized controlled trial has tested BPC-157 for tendon injury in humans
The Achilles Tendon Studies: Where It Started
The foundational study for BPC-157 in tendon injury was published by Staresinic and colleagues in 2003. Rats received complete transection of the Achilles tendon, followed by BPC-157 or saline treatment. The peptide-treated group showed accelerated healing across multiple endpoints:[2]
Biomechanical improvements:
- Increased load to failure (the force required to re-rupture the healing tendon)
- Higher Young's modulus of elasticity (a measure of the tendon's stiffness and structural integrity)
Histological improvements:
- More organized collagen fiber formation
- Shift from inflammatory granulocytes to reparative mononuclear cells
- Superior fibroblast formation
- Better reticulin and collagen architecture
Functional improvements:
- Higher Achilles functional index (AFI) values, indicating improved gait mechanics
- Smaller and shallower tendon defects at the injury site
- Reestablishment of full tendon integrity
The study also included in vitro work showing that BPC-157 directly stimulated tendocyte (tendon cell) proliferation, establishing that the healing effect was not solely indirect via anti-inflammatory or angiogenic mechanisms.
Krivic and colleagues followed up in 2006 with a study on Achilles tendon detachment from bone in rats, testing whether BPC-157 could promote tendon-to-bone healing, a notoriously difficult repair problem. The peptide promoted healing at the enthesis (the tendon-bone junction) and counteracted the aggravating effects of corticosteroid administration, which is clinically relevant because corticosteroid injections are frequently used for tendon pain despite evidence that they impair healing.[3]
How BPC-157 Acts on Tendon Cells
The cellular mechanisms were dissected by Chang and colleagues in two studies that moved beyond the observation of healing to identify specific pathways.
The FAK-Paxillin Migration Pathway
Chang et al. (2011) demonstrated three distinct cellular mechanisms by which BPC-157 promotes tendon repair:[4]
-
Tendon outgrowth: BPC-157 promoted the ex vivo outgrowth of tendon fibroblasts from tendon explants, meaning the peptide encouraged tendon cells to migrate out from damaged tissue to bridge the gap at an injury site.
-
Cell survival: Under oxidative stress conditions (hydrogen peroxide exposure), BPC-157-treated tendon fibroblasts survived at higher rates than untreated controls. Oxidative stress is a major contributor to cell death in injured tendons, particularly in the hypoxic core of the healing zone.
-
Cell migration: BPC-157 stimulated tendon fibroblast migration through activation of the focal adhesion kinase (FAK)-paxillin signaling pathway. FAK is a tyrosine kinase that integrates signals from the extracellular matrix with intracellular cytoskeletal dynamics; when activated, it promotes cell movement toward the injury site.
Growth Hormone Receptor Upregulation
Chang et al. (2014) identified an additional mechanism: BPC-157 increased growth hormone receptor (GHR) expression in tendon fibroblasts.[5] Growth hormone signaling through GHR activates the JAK2-STAT pathway, which drives collagen synthesis and cell proliferation. By upregulating the receptor itself, BPC-157 potentially amplifies the tendon's responsiveness to circulating growth hormone, an indirect mechanism that could enhance healing without the peptide itself being present at the injury site continuously.
This receptor upregulation finding is mechanistically interesting but has limitations. The study was in vitro (cell culture, not living animals), and whether the GHR upregulation is sufficient to produce clinically meaningful increases in local growth hormone signaling within a healing tendon in vivo is unknown.
The Angiogenesis Connection
Brcic and colleagues (2009) specifically examined BPC-157's effect on blood vessel formation during tendon and muscle healing.[6] Tendons heal slowly in part because they have limited vascularity compared to muscle or skin. New blood vessel formation (angiogenesis) in the healing zone is critical for delivering the oxygen, nutrients, and repair cells needed for tissue regeneration.
BPC-157 modulated angiogenesis in both muscle and tendon healing models, promoting earlier formation of new blood vessels in the repair zone. The peptide's interaction with the VEGFR2 signaling pathway appears to be central to this effect. VEGF-mediated angiogenesis is beneficial for healing but carries theoretical oncological implications, a topic explored in BPC-157 and Cancer Risk.
Beyond Tendons: Ligament and Joint Evidence
Ligament Healing
Cerovecki and colleagues (2010) tested BPC-157 (under its pharmaceutical designation PL 14736) in rat medial collateral ligament (MCL) injury. The peptide improved ligament healing outcomes, extending the evidence from tendon to another dense connective tissue type.[7] For the full evidence on connective tissue repair, see BPC-157 and Ligament Healing.
Intra-Articular Injection for Knee Pain
Lee and colleagues (2021) reported on the use of intra-articular BPC-157 injection for multiple types of knee pain.[8] This study represented a departure from the purely preclinical model, though its design (case series, not randomized controlled trial) limits the conclusions that can be drawn. Pain reduction and functional improvement were reported, but without a control group, placebo effects cannot be excluded.
The Systematic Review Evidence
Vasireddi et al. (2025): The HSS Journal Systematic Review
The most comprehensive evaluation of BPC-157 for musculoskeletal injuries was published in 2025 in the HSS Journal (Hospital for Special Surgery).[1] After screening 544 articles, the reviewers included 36 studies: 35 preclinical and 1 clinical. Their findings:
- Preclinical models consistently showed BPC-157 improved functional, structural, and biomechanical outcomes in tendon, ligament, muscle, and bone injuries
- No study assessed the safety or adverse events of BPC-157 in humans in a controlled manner
- The overall quality of evidence was rated as low, primarily due to the absence of human data and reliance on a small number of research groups
Gwyer et al. (2019): The Earlier Review
Gwyer and colleagues published an earlier review of BPC-157's role in musculoskeletal healing, noting the peptide's consistent positive effects across animal models but flagging the lack of clinical translation as a critical gap.[9]
McGuire et al. (2025): Regeneration or Risk?
A narrative review titled "Regeneration or Risk?" examined BPC-157 for musculoskeletal healing and explicitly weighed the preclinical promise against the unknown risk profile.[10] The review highlighted the tension between a large body of positive animal data and an absence of the safety, dosing, and efficacy data from controlled human trials that would be required for clinical recommendations.
The First Human Safety Data
Lee and colleagues (2025) published the first IRB-approved safety study of intravenous BPC-157 in humans.[11] The study enrolled 2 participants who received escalating doses over 3 days: 10 mg on day 1, 20 mg on day 2, and 40 mg on day 3, each infused in 250 cc normal saline over one hour. Baseline and post-infusion blood work and vital signs were collected.
No adverse events were reported. Vital signs and laboratory values remained within normal ranges throughout the study period.
The limitations of this study are severe and should not be overlooked:
- Two participants provide essentially no statistical power to detect adverse events
- Three days of dosing cannot identify chronic or delayed toxicity
- The study was designed to assess safety only, not efficacy for tendon or any other injury
- The route (intravenous) differs from the subcutaneous or local injection routes commonly used in clinical practice
- The doses used (10-40 mg IV) may not correspond to therapeutically relevant tissue concentrations for tendon healing
This pilot demonstrates that intravenous BPC-157 did not cause acute catastrophic adverse events in 2 people over 3 days. It does not establish that BPC-157 is safe for tendon injury treatment.
Why Athletes Use It Despite the Gaps
The disconnect between evidence and adoption is striking. BPC-157 is widely used by athletes despite zero randomized controlled trials for any musculoskeletal indication, WADA prohibition, and FDA non-approval. The drivers of adoption include:
- Social media and podcast promotion (particularly in MMA, CrossFit, and bodybuilding communities)
- Compelling animal data that is readily accessible online and easy to extrapolate (even when extrapolation is premature)
- Limited effective treatments for chronic tendon injuries (tendinopathy remains clinically frustrating)
- Perception of BPC-157 as "natural" because it derives from a gastric juice protein (the synthetic peptide used in practice is manufactured, not extracted)
- Availability through compounding pharmacies and gray market peptide vendors without prescription requirements in many jurisdictions
The collagen peptides approach represents the evidence-based alternative for sports rehab, with multiple randomized trials in humans, though the outcomes measured and injury types differ substantially from what BPC-157 targets.
The Gaps That Matter
Single research group dominance: The majority of BPC-157 tendon studies originate from the Sikiric laboratory at the University of Zagreb. The Chang laboratory (Taiwan) has contributed mechanistic work, and the 2025 systematic reviews represent independent assessment. Independent replication of the core Achilles tendon findings by unaffiliated groups is limited.
Species gap: Rat tendons heal faster than human tendons, are structurally simpler, and experience different mechanical loading patterns. Compounds that accelerate rat tendon healing have a poor track record of translating to human clinical benefit across the orthopedic literature.
Dose translation: Animal doses (typically 10 mcg/kg or 10 ng/kg intraperitoneally in rats) cannot be directly converted to human doses without pharmacokinetic studies that have not been completed. The route of administration matters: intraperitoneal injection in rats, subcutaneous injection in human practice, and local injection at the injury site all produce different tissue concentration profiles.
Long-term outcomes: No study has followed tendon healing outcomes beyond the acute repair phase to assess re-rupture rates, return to sport timelines, or long-term functional recovery.
Regulatory vacuum: BPC-157 occupies a space between regulated pharmaceutical and dietary supplement where quality control, purity, and dosing accuracy of commercially available products are unverified.
The Bottom Line
BPC-157 has demonstrated consistent tendon healing benefits across 23 years of rat studies, including improved biomechanical strength, enhanced histological organization, and identified cellular mechanisms (FAK-paxillin pathway activation, growth hormone receptor upregulation, angiogenesis promotion). The evidence base has a fundamental structural weakness: 35 preclinical studies, zero randomized controlled trials in humans, and a first safety pilot involving only 2 participants. Athletes use it widely based on extrapolation from animal data, social media promotion, and frustration with conventional tendon injury treatments.